Category: AI & MI

Hackathon Diaries #4 FaceFinder: Face Recognition Application

Hackathon Diaries #4 FaceFinder: Face Recognition Application

Hey there tech enthusiasts. Welcome to the fourth edition of Hackathon Diaries, where we present to you the latest and greatest innovations created by the brilliant minds at INT. Hackathon 2023. Hold on to your hats because this time we’re taking things up a notch with our cutting-edge solution, FaceFinder. It’s all about securing today for a safer tomorrow, and we’re thrilled to share all the exciting details with you. FaceFinder Picture this: You arrive at your workplace, but instead of fumbling around with keys or access cards, you just stand in front of the gate and let FaceFinder work its magic.  It is an application to open gates securely and automatically through facial recognition technology. It facilitates users to upload/register images of their faces, which can be used to recognise them. The stored image in the database will be used to verify any new entry request. It grants access to matching, otherwise,  the gate won’t open and physical intervention will be needed. The Techie  V Sweta Working Flowchart But let’s get into the nitty-gritty of how it all works. Our brilliant tech-savvy superstar has designed an innovative flowchart that seamlessly integrates various tools to make FaceFinder a robust and reliable solution.  Tech Stack We’re talking about:  ASP.NET Core at the backend Azure Cognitive Service Computer Vision and Face API for detecting and recognising people Azure Storage account to store all your pretty faces And of course, Entity Framework Core is there to make sure everything is stored in our trusty SQL server Now, let’s talk benefits Enhanced Security: Using facial recognition technology to open gates can enhance the security of the premises by ensuring access to only authorised individuals Convenience: With this application, users can open gates without having to manually unlock them Efficiency: Automatic gate opening saves time and effort for individuals who frequently access the premises Enhanced User Experience: The intuitive UI/UX of the application makes it hassle-free for users accessing the gateway Cost Savings: Reduces the need for security personnel, thereby cutting costs associated with staffing and training. It also eliminates the requirement for physical access controls such as keys or access cards, which can be expensive to produce and maintain. Potential Challenges Of The Prototype and The Future Opportunities But we’re not going to shy away from potential challenges. FaceFinder has a few limitations, like being unable to recognise identical twins, finding it difficult to identify individuals with facial injuries, and struggling to identify those wearing a cap or scarf.  Hey, we’re not giving up on these. We’re already working on ways to improve FaceFinder, such as implementing IoT devices, maintaining a block list to restrict specific individuals, initiating breaching alerts, enhancing scalability, reducing response time, and exploring more use cases. So, there you have it. FaceFinder is the future of secure and convenient gate access, and we’re excited to take this technology to new heights. Stay tuned for more exciting developments from Hackathon Diaries.

Read More »
Addressing drug shortages with advanced analytics

Addressing drug shortages with advanced analytics

Drug shortages have become a part and parcel of modern healthcare systems due to several reasons. While there is a sizeable economic impact of drug shortages for manufacturers and pharmacies alike, there are widespread community and social disadvantages as well. Pharmacies or clinics running out of medicine stocks are representatives of a scenario that is often witnessed worldwide and with frightening consequences.  For example, Europe is already seeing shortages of commonly-used medicines. A survey by the Pharmaceutical Group of the European Union (EU) had 100% of 29 member nations reporting shortages of medicines amongst community pharmacists. 76% also stated how shortages had worsened than the earlier year (the survey was implemented between 14th November and 31st December 2022). The UK is also witnessing HRT shortages according to reports, while hospitals in the U.S. are also reporting issues with procurement for liquid ibuprofen, while ADHD diagnoses have gone up in the U.S. as well, leading to shortages of vital drugs for the same. Mexico is witnessing chronic shortages and unfulfilled prescriptions and supply fluctuations and disruptions have been seen widely throughout Asia too.  What are the reasons for medicine shortages?  Wondering about the reason for drug shortages? There are quite a few that can be noted in this context:  Higher seasonal illness outbreaks in the aftermath of COVID-19, leading to skyrocketing average annual demand for medicines that is higher than normal in several categories.  The inability of pharmaceutical companies to meet such unprecedented demand, with excess capacity restricted for cost control.  Global supply chain impact along with higher energy costs and inflation have impacted global drug manufacturers who have to contend with pricing measures.  Stockpiling by customers due to sudden drug shortages.  Over-prescribing by the system.  Reports estimate that the National Health Service in the UK loses a whopping 300 million pounds annually owing to partially-used or unused medication which cannot be reused or recycled.  Lack of systems for forecasting and identifying supply shortages, while ensuring proper inventory management.  Drug Shortage Solutions That May Work  There are a few drug shortage solutions that may be effective for combating and reducing shortages.  Data and analytics are enabling better access towards medicines worldwide while enabling superior supply and demand management for individual patients and pharmacies alike.  Real-time pharmacy, hospital, and clinical data will enable a proper understanding of the demand for specific drugs/medical products.  Leveraging electronic and public health records for enabling healthcare stakeholders to report demand figures for drugs, without revealing confidential patient data.  Opportunities for better inventory and supply chain management with AI (artificial intelligence) and machine learning (ML).  Generic entities may leverage smarter technologies for lowering manufacturing costs by up to 20% while enhancing production. Smarter and connected factories with proper insights and data analysis can enable higher savings and reliable deliveries.  Companies may look at higher procurement of local active ingredients while depending on go-to nations for the same. Boosting supply and production levels, along with harnessing real-time data analytics will enable tackling this scenario.  Supervised machine learning and analytics models can help in forecasting/predicting shortages for most drugs used throughout various categories, price points, and age groups.  Modelling can enable healthcare stakeholders to understand more about the issues behind drug shortages while analytics can also help predict demand for specific drugs based on historical data and current trends.  Pharmacies and other players may not have access to data on the supply side, although they have demand-side information. They will be able to gain more visibility into the supply chains of manufacturers with an integrated information-sharing system.  Data analytics-driven insights for optimizing orders and eventually lowering the effect of drug shortages on pharmaceutical and healthcare operations.  Systems for tracking and reporting drug shortages, including aspects like the frequency, drugs involved, period, causes, duration, managing strategies, impacts, and future shortages too.  Real-time identification and tracking of patients receiving shorter supplies of drugs by hospitals, clinics, and pharmacies. Immediate patient identification regulations for capturing present drug utilization across multiple categories.  Real-time identification and addressing situations along with finding out drugs in shorter supply. Predictive abilities enable higher time for researching material for alternative agents or making suitable arrangements for drug acquisition from other sites or facilities.  Once supply levels normalize for a drug, pharmacists and healthcare stakeholders may discontinue their surveillance regulations without waiting for technical assistance. Real-time data-filtering and reporting abilities are leveraged for viewing drug usage trends and prescription patterns throughout healthcare systems. These insights may enable higher standardization of drug management across institutions, while also facilitating better training of clinicians for lowering care variations.  Advanced data analytics will help address drug shortages and enable better inventory management simultaneously. However, suitable implementation, technological integration, and awareness are necessary for the same.  FAQs How can advanced analytics be used to address drug shortages? Advanced analytics can be deployed for tackling drug shortages through real-time tracking and surveillance of prescription trends and drug demand, forecasting shortages, and enabling better drug supply management.  What are the benefits of using advanced analytics to address drug shortages? Advanced analytics goes a long way towards helping tackle drug shortages, enabling forecasting future demand and shortages, identifying patterns for better management, and also enabling better global medicine access.  What are the challenges of using advanced analytics to address drug shortages? Challenges include technological integration, legacy systems integration, awareness regarding best practices, quality data generation, and more.  What are the best practices for implementing advanced analytics for drug shortage management? Best practices include unified and integrated public databases, suitable data modelling systems, suitable protocols for data security and privacy, and swift reporting mechanisms for demand and shortages.

Read More »
Data analytics plays a crucial role in clinical trial design and analysis by providing valuable insights into the effectiveness of new treatments and therapies.

The role of data analytics in clinical trial design and analysis

What is the role of data analysis in clinical trials? Can there be better clinical trial data analysis using R and other technologies? Is there a case for using big data analysis in clinical trials? Experts would certainly say Yes to all these questions. Clinical trials themselves have gone through sweeping changes over the last decade, with several new developments in immunotherapy, stem cell research, genomics, and cancer therapy among numerous segments. At the same time, there has been a transformation in the implementation of clinical trials and the process of identifying and developing necessary drugs.  To cite a few examples of the growing need for clinical trial data analysis, researchers gain quicker insights through the evaluation of databases of real-world patient information and the generation of synthetic control arms, while identifying drug targets alongside. They can also evaluate drug performance post-regulatory approvals in this case. This has lowered the cost and time linked to trials while lowering the overall burden on patients and enabling faster go-to-market timelines for drugs too.  What is driving data analysis in clinical trials?  Clinical trial data analysis is being majorly driven by AI (artificial intelligence) along with ML (machine learning), enabling the capabilities of collection, analysis, and production of insights from massive amounts of real-time data at scale, which is way faster than manual methods. The analysis and processing of medical imaging data for clinical trials, along with tapping data from other sources is enabling innovation of the entire process while being suitable for supporting the discovery procedure in terms of quickening the trials, go-to-market approaches, and launches.  The data volumes have greatly increased over the last few years, with more wearable usage, genomic and genetic understanding of individuals, proteomic and metabolomic profiles, and detailed clinical histories of patients derived from electronic health records. Reports indicate 30% of the data volumes of the world are generated by the global healthcare industry. The CAGR (compound annual growth rate) for healthcare data will touch 36% by the year 2025 as well. The volume of patient data in clinical systems has already grown by a whopping 500% to 2020 from 2016.  Data analysis in clinical trials- What else should you note?  Here are a few factors that are worth noting:  Synthetic control arm development  The role of data analysis in clinical trials is even more evident when one considers the development of synthetic control arms. Clinical drug discovery and trials may be fast-tracked while enhancing success rates and designs of clinical trials. Synthetic control arms may help in overcoming challenges linked to patient stratification and also lower the time required for medical treatment development. It may also enable better recruitment of patients through resolving concerns about getting placebos and enabling better management of diverse and large-sized trials.  Synthetic control arms tap into both historical clinical trials and real-world data for modelling patient control groups and doing away with the requirement for the administration of placebo treatments for patients which may hinder their health. It may negatively impact patient outcomes and enrolment in trials. The approach may work better for rare ailments where populations of patients are tinier and the lifespan is also shorter owing to the disease’s virulent nature. Using such technologies for clinical trials and bringing them closer to end-patients may significantly lower the overall inconveniences of travelling to research spots/sites and also the issue related to consistent tests.  ML and AI for better discovery of drugs ML and AI may enable a quicker analysis of data sets gathered earlier and at a swifter rate for clinicians, ensuring higher reliability and efficiency in turn. The integration of synthetic control arms in mainstream research will offer new possibilities in terms of transforming the development of drugs.  With an increase in the count of data sources including health apps, personal wearables and other devices, electronic medical records, and other patient data, these may well become the safest and quickest mechanisms for tapping real-world data for better research into ailments with sizeable patient populations. Researchers may achieve greater patient populations which are homogenous and get vital insights alongside. Here are some other points worth noting:  The outcomes of clinical trials are major metrics with regard to performance, at least as far as companies and investors are concerned. They are also the beginning of collaborations between patients, groups, and the healthcare sector at large. Hence, there is a clearly defined need for big data analysis in clinical trials as evident through the above-mentioned aspects.  FAQs How can data analytics be used in clinical trial design and analysis? Data analytics can be readily used for clinical trial design and analysis, expanding patient selection criteria, swiftly sifting through various parameters and helping researchers better target matching patients who match the criteria for exclusion and inclusion. Data analysis methods also enable better conclusions from data while also improving clinical trial design due to better visibility of the possible/predicted risk-reward outcomes.  What are the benefits of using data analytics in clinical trial design and analysis? The advantages of using data analytics in clinical trial design and analysis include the integration of data across diverse sources, inclusive of third parties. Researchers get more flexibility in terms of research, finding it easier to analyze clinical information. Predictive analytics and other tools are enabling swifter disease detection and superior monitoring.  What are the challenges of using data analytics in clinical trial design and analysis? There are several challenges in using data analytics for the analysis and design of clinical trials. These include the unavailability of skilled and experienced resources to implement big data analytics technologies, data integration issues, the uncertainty of the management process, storage and quick retrieval aspects, confidentiality and privacy aspects and the absence of suitable data governance processes.  What are the best practices for implementing data analytics in clinical trial design and analysis? There are numerous best practices for the implementation of data analytics for the analysis and design of clinical trials. These include good clinical data management practices, clinical practices, data governance

Read More »
MENU
CONTACT US

Let’s connect!

Loading form…

CONTACT US

Let’s connect!

    Privacy Policy.

    Almost there!

    Download the report

      Privacy Policy.